SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to a sharp decline in its stock price, sparking community concern and speculation about the reasons behind it, including the potential impact of the DVLT deal and the company's leadership. Some investors are questioning the company's direction, while others are anticipating a potential short squeeze or positive news to reverse the current trend. Discussions also involve the possibility of a strategic play related to Semnur and its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

TDOC is trending as community members discuss its potential for a short squeeze, citing high short interest and upcoming catalysts. Bullish sentiment is fueled by mentions of technical indicators, such as breaking above key moving averages, and speculation around potential AI integration and partnerships. Some investors express frustration with the stock's historical performance and management, while others remain optimistic about its long-term growth potential in the telehealth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC). Investors who...

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! FULC INVESTOR ALERT: Bronstein...

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) plunged 61.1% on Sept.
read more...

Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views

Latest Ratings for FULC
 DateFirmActionFromTo Mar 2022OppenheimerInitiates Coverage OnOutperform Aug 2021HC Wainwright & Co.MaintainsBuy Aug 2021SVB LeerinkMaintainsOutperform
 View More Analyst...

Shares of Fulcrum Therapeutics, Inc. (FULC) plummeted nearly 70% on Thursday, making it the biggest loser across U.S. exchanges, after the company announced the failure of its drug candidate aimed at treating a rare muscle disorder .The Phase 3 REACH trial for losmapimod, an experimental drug aimed at treating facioscapulohumeral muscular dystrophy (FSHD), did not meet its primary or secondary endpoints.FSHD, a rare genetic disorder that causes muscle weakness and wasting, reportedly affects about four in 100,000 individuals.Losmapimod was positioned to become the first approved therapy for this progressive muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.The trial’s failure is a particularly harsh blow given Sanofi’s recent $80 million bet on losmapimod just four months ago. The licensing deal carried hopes that late-stage success could propel the p38 inhibitor into a first-of-its-kind treatment for FSHD.Sanofi’s U.S.-listed shares were down 1.3% on the Nasdaq following the news.With $273.8 million in cash and equivalents, Fulcrum plans to shift focus to its remaining pipeline, led by pociredir, a Phase 1-stage drug for sickle cell disease that aims to increase fetal hemoglobin expression.However, the outlook remains bleak as analysts slashed their ratings and price targets on the stock.Stifel downgraded Fulcrum to ‘Hold’ from ‘Buy’, cutting its price target to $3 from $22, citing the “logical” but “disappointing” decision to discontinue losmapimod development.BofA dropped its rating to ‘Underperform’ from ‘Neutral’ and reduced its price target to $2 from $10.Leerink downgraded the stock to ‘Market Perform’ from ‘Outperform’ with a price target of $4, down from $16, pointing to high stakes and a lack of approved therapies for FSHD.Retail sentiment on Stocktwits turned sharply negative, to ‘extremely bearish’ (17/100), accompanied by increased message volume.<figure class="image"><a href="https://stocktwits.com/symbol/FULC"><img style="aspect-ratio:1314/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FULC_retail_sentiment_and_message_volume_scores_Sep_12_11b09f649a.png" alt="FULC retail sentiment and message volume scores Sep 12.png" width="1314" height="308"></a><figcaption>FULC retail sentiment and message volume scores Sep 12</figcaption></figure>One user lamented, “$FULC biggest risky play in a long time turned into my biggest loss in a long time. Sorry folks.”<stembedurl>https://stocktwits.com/RonIsWrong/message/585814681</stembedurl>Another bearish watcher predicted further declines, stating, “$FULC they have nothing else in the pipeline, going to 1.”<stembedurl>https://stocktwits.com/petoss/message/585822022</stembedurl>FULC stock has lost more than half of its value this year.Read next: <a href="https://stocktwits.com/news/markets/equity/berkshire-stock-falls-after-ajit-jain-slashes-stake/c7zxwMbR5T">Berkshire Hathaway Shares Dip After Insurance Chief Ajit Jain Slashes Stake In Firm By Over 50%: Retail Holds Strong</a>

Top Wall Street Loser Fulcrum Therapeutics Drags Retail Sentiment To Ground After Drug Trial Fails, Analysts Slash Ratings

Losmapimod was positioned to become the first approved therapy for a rare muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.

Equity

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ...

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.
read more...

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

 Futures are trading higher ahead of today's PPI report, extending on yesterday's post-NVDA rebound momentum, as a rally that...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$9.28
Prev Close	$9.51
Open	$9.63
Dividend Yield	0.00%
50-Day Moving Average	$7.23
Beta	1.48
Avg. Volume	519,061.57
PE Ratio	-7.83

52-Week High	$9.56
52-Week Low	$2.32
Market Capitalization	$514.41M
EPS (Annual)	-$0.1569
Price to Book	2.40
Revenue Per Employee	$1.78M
Enterprise Value/EBITDA	N/A

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FULC News

FULC Fulcrum Therapeutics Inc